Search This Blog

Tuesday, July 7, 2026

Multifocal Noninvasive Deep Brain Stimulation to Enhance Cognition in Mild Cognitive Impairment

 

  1. Umberto Nencha, MD1,2,3; Monika Pupíková, PhD4; Margaux di Natale, MS1,2

Key Points

Question  Does synergistic, dual-target, noninvasive neuromodulation of the striatum and cerebellum improve working memory (WM) in individuals with mild cognitive impairment (MCI), particularly those with early striatal degeneration?

Findings  In this randomized, quadruple-blind, placebo-controlled crossover trial of 41 patients with MCI, dual-target stimulation significantly improved WM accuracy in individuals with early striatal degeneration. Stimulation-related gains were associated with striatal functional connectivity and cerebellar volume.

Meaning  These findings suggest that targeted engagement of cerebello-striatal circuits through coordinated dual-target noninvasive neuromodulation may represent a promising strategy to enhance WM in early stages of a neurodegenerative disease.

Abstract

 Multifocal Noninvasive Deep Brain Stimulation to Enhance Cognition in MCI
Visual Abstract.

Importance  Impairment of working memory (WM), which relies on distributed cortical and subcortical structures, including cerebello-striatal pathways, is a core contributor to functional decline in patients with mild cognitive impairment (MCI) and dementia. Because the striatum is affected early in dementia, whereas the cerebellum remains relatively preserved, the cerebellum may offer support for maintaining striatal function in neurodegenerative diseases.

Objective  To evaluate whether sequential cerebellar transcranial magnetic stimulation (TMS) and striatal transcranial temporal interference stimulation (tTIS) enhances WM in patients with MCI, especially those with early striatal degeneration, like MCI with Lewy bodies (MCI-LB).

Design, Setting, and Participants  This randomized, quadruple-blind, placebo-controlled, crossover trial was conducted from August 2023 to October 2024 at 1 site in Switzerland and 1 in Czech Republic. Participants included individuals with MCI-LB or amnestic MCI (aMCI) and age-matched healthy controls (HCs).

Intervention  Three pseudorandomized single stimulation sessions: (1) cerebellar TMS followed by striatal tTIS, (2) control TMS followed by striatal tTIS, and (3) an active control combining control TMS with control striatal tTIS.

Main Outcomes and Measures  The primary outcomes were changes in accuracy and correct answer reaction times in a visual WM task with varying memory loads and distractors. Modulators included resting-state functional connectivity and gray-matter volume in WM-related regions. Linear mixed-effects models were used to examine the main effects of stimulation condition on accuracy and reaction times.

Results  Forty-one patients with MCI, including 21 with MCI-LB (16 female [76%]; mean [SD] age, 71.05 [6.84] years) and 20 with aMCI (11 female [55%]; mean [SD] age, 72.30 [7.50] years), and 20 HCs (10 female [50%]; mean [SD] age, 69.5 [4.42] years) were analyzed. In patients with MCI-LB, cerebellar TMS plus striatal tTIS increased accuracy in distractor trials compared with the active control (control TMS plus control tTIS, P < .001; d = −0.77) and striatal tTIS alone (control TMS plus striatal tTIS, P = .004; d = −0.60). Greater accuracy gains were associated with lower putaminal connectivity (r = −0.66; P = .03). In patients with aMCI, cerebellar volumes showed associations with task performance in both distractor trials (cerebellar TMS plus striatal tTIS, R2 = 0.27; P = .02) and high-load trials (control TMS plus striatal tTIS, R2 = 0.24; P = .03), and larger volumes were associated with faster responses; however, significant behavioral differences between active and control stimulation conditions were not observed. No serious adverse events occurred.

Conclusions and Relevance  Synergistic dual-target cerebellar TMS and striatal tTIS improved WM in MCI-LB, particularly in patients with lower striatal connectivity, suggesting dual-targeted neuromodulation as a potential therapeutic avenue in neurodegenerative disorders.

Trial Registration  ClinicalTrials.gov Identifier: NCT07090681

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2851135

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.